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Abstract: Myelin protein zero (P0), a type I transmembrane protein, is the most abundant protein
in peripheral nervous system (PNS) myelin—the lipid-rich, periodic structure of membrane pairs
that concentrically encloses long axonal segments. Schwann cells, the myelinating glia of the PNS,
express P0 throughout their development until the formation of mature myelin. In the intramyelinic
compartment, the immunoglobulin-like domain of P0 bridges apposing membranes via homophilic
adhesion, forming, as revealed by electron microscopy, the electron-dense, double “intraperiod line”
that is split by a narrow, electron-lucent space corresponding to the extracellular space between
membrane pairs. The C-terminal tail of P0 adheres apposing membranes together in the narrow
cytoplasmic compartment of compact myelin, much like myelin basic protein (MBP). In mouse
models, the absence of P0, unlike that of MBP or P2, severely disturbs myelination. Therefore, P0 is the
executive molecule of PNS myelin maturation. How and when P0 is trafficked and modified to enable
myelin compaction, and how mutations that give rise to incurable peripheral neuropathies alter the
function of P0, are currently open questions. The potential mechanisms of P0 function in myelination
are discussed, providing a foundation for the understanding of mature myelin development and how
it derails in peripheral neuropathies.
Keywords: myelin; myelination; development; peripheral neuropathies; protein folding;
transmembrane protein; protein-membrane interaction; protein-protein interaction
1. Introduction
Myelin is required for axonal saltatory conduction in the central and peripheral nervous systems
(CNS and PNS, respectively) of vertebrates [1]. While involved in the structural and trophic support
of the axon itself [2–5], the insulative character of myelin arises from a highly specialized plasma
membrane, which is wrapped around selected axonal segments through a mechanism powered by
actin disassembly [6]. After several dozen wraps, myelin-specific proteins trigger compaction of
myelin, forming a highly periodic lipid-rich structure with very low water content of only ~40% of the
total myelin mass [7–9]. In the PNS, each separate myelin unit along an axon originates from a single
glial cell, the Schwann cell, which matures from a Schwann cell progenitor cell (SCP). These in turn
arise from the neural crest during early post-natal development along with other glial cells [10]—a
proliferation pathway that is not present in the CNS. Oligodendrocytic myelination in the CNS is
arranged differently to that in the PNS [11], although the mature myelin sheaths in both the CNS and
PNS morphologically resemble each other [12].
The greatest biochemical difference between the multilamellar (i.e., compact) membranes of CNS
and PNS myelin lies in their respective proteomes [13,14]. CNS and PNS myelin are highly enriched in
a mere handful of proteins, which is an unusual feature in most biological systems. Many of these
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proteins are multifunctional [15–21], contain large stretches of intrinsic disorder [12], tolerate highly
hydrophobic conditions [22], and have extended lifetimes [23]. While there is some overlap between
the CNS and PNS myelin proteomes [13,14], proteins that are specific either to the CNS or the PNS are
present especially in compact myelin, which forms the insulative bulk of the myelin sheath. CNS- and
PNS-specific proteins that do not share sequence homology appear to perform overlapping roles in
stabilizing compact myelin [24]. The dominant compact myelin proteins in the CNS are myelin basic
protein (MBP) and proteolipid protein (PLP) [13,14], whereas in the PNS, myelin protein zero (P0, also
known as MPZ) constitutes the largest protein fraction, mostly accompanied by MBP and peripheral
myelin proteins 2 and 22 (P2 and PMP22, respectively) [14,25]. All of these proteins are involved in
adhering apposing membrane leaflets together [24,26–28], forming the fundamental basis of compact
myelin stability.
Compact myelin must remain stable to ensure myelin-facilitated insulation; mutations that
compromise the structure or function of myelin proteins, or autoimmunogenic events that involve
these proteins may result in crippling incurable diseases that involve demyelination—the systematic
destruction of myelin and its insulative ultrastructure. These conditions include peripheral neuropathies
in the PNS, such as Charcot–Marie–Tooth disease (CMT) and Dejerine–Sottas syndrome (DSS) [29,30],
and multiple sclerosis in the CNS [31]. Over 70 CMT and DSS mutations have been described for P0
alone [32]. Some mutations severely truncate P0, some act by disturbing the molecular mechanisms of
P0-mediated myelination, and some by triggering the unfolded protein response (UPR) [33–35], which
likely arises from P0 misfolding or other related mechanisms that cannot be cleared by endoplasmic
reticulum (ER)-associated protein degradation (ERAD) [36].
The narrow extracellular space between pairs of compact myelin membranes, the intramyelinic
compartment, is compacted by a densely arranged P0 zipper in the PNS, which dictates the stability
and width of this compartment [28,37–41]. While numerous studies have specifically focused on the
compaction of the intramyelinic compartment, P0 has also been shown to stabilize membrane stacking
in the narrow cytoplasmic compartment [42,43]; this is supported by recent biophysical experiments
using model membranes [41,44]. In animal models, the stacking occurs in the absence of cytosolic MBP
and P2 [42,45,46], which poses open, neglected questions, as cytoplasmic membrane leaflet adhesion by
P0 remains poorly understood. In addition, the basal expression of P0 before the onset of myelination
raises doubts about the apparent redundancy of P2 and MBP [47], especially since MBP is an essential
membrane stacker in CNS myelin [17], and both MBP and P2 are required for the long-term stability
and the correct ultrastructure formation of PNS myelin [46,48]. These questions will serve as the major
focus of this short review, which aims to motivate further studies in the field—especially those that are
not dependent on simplified model systems—in order to establish a complete model of P0 and its role
as an executive factor of PNS myelination.
2. The Molecular Structure of P0
P0 is a plasma membrane-localized type I transmembrane protein that consists of a 120-residue
N-terminal extracellular immunoglobulin (Ig)-like domain, a single 30-residue transmembrane helix,
and a 70-residue C-terminal cytoplasmic tail (P0ct) (Figure 1a). P0 exists predominantly as a single
translated isoform, although recently a longer isoform (L-MPZ) of unknown function has been described.
L-MPZ is produced through a stop-codon readthrough and as such differs in the length of the C-terminal
extension [49,50]. Upon expression, P0 and L-MPZ are produced as precursors that contain a 30-residue
N-terminal signal peptide sequence, which is cleaved off during membrane insertion [51]. The only
known close homolog of P0 is MPZ-like protein 1 (MPZL1, also known as PZR [52]), which is expressed
in many tissues outside the PNS and functions as a plasma membrane-bound signaling receptor [52–54].
The Ig-like domain is the only part of P0 that has been characterized at high resolution
(Figure 1b) [37,40]. The domain is a pair of β-sheets stabilized by a single intramolecular disulfide
between two conserved cysteine residues (Figure 1b,c) [37,40,55]. The Ig-like domain is structurally
very similar to the Ig-like domain in MPZL1, although they share only ~46% sequence identity [56].
Cells 2020, 9, 1832 3 of 21
P0ct differs drastically from the Ig-like domain, as it has a compositional bias typical for intrinsically
disordered proteins (IDPs) [57] and is highly positively charged, much like MBP [12,17]. Systematic
biophysical characterizations using simplified lipid compositions have been performed on P0ct, which
revealed that P0ct alone is an IDP in solution but folds upon irreversible association with negatively
charged detergent micelles and lipid vesicles [58–61]. P0ct embeds deep into the lipid structure and
affects the mechanical and thermodynamic properties of its surroundings [41,44]. This association in
simplified model systems is influenced by ionic strength and the presence of Ca2+ [62], and it generally
resembles the behavior of MBP under similar conditions, which involves a large gain of structural
content [41,58–61,63]. The association is of electrostatic origin, and the subsequent insertion is thought
to arise from the charge neutralization of P0ct by the negatively charged membrane field, which
would allow P0ct to fold and potentially display surface chemistry that allows it to interact with the
hydrophobic lipid tails. The formation of amphipathic structures is possible, but further structural
studies are required in this respect. Another interesting aspect is the ability of MBP to interact with the
cytoskeleton, and P0ct has historically been hypothesized to do the same [64]. Generally, P0 is highly
conserved throughout vertebrates, especially in mammals (Figure 1c). P0 has been shown to undergo
dimerization via forming Gly zippers through a conserved motif of evenly spaced Gly residues in the
transmembrane domain [65].
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highlighted in red. Fatty acylation of P0ct is shown in green, with the position Cys182 in P0ct indicated 
with an asterisk. Phospholipids and glycolipids are shown with white and gray headgroups, 
respectively. TM, transmembrane. (b) Structures of the rat (blue; PDB ID 1NEU [37]) and human (red; 
PDB ID 3OAI [40]) P0 Ig-like domains. The conserved disulfide bridge is indicated with an arrow. (c) 
Sequence alignment of the predominant P0 isoform from selected vertebrates. The signal sequence 
has been omitted, and the numbering and secondary structure labels correspond to human P0. The 
disulfide-linked cysteines (asterisks), the fatty acylation site (F), the glycosylation site (S), and the Gly 
zipper (G) motif in the transmembrane domain are indicated. Known phosphorylation sites are 
labelled (P). The P-site in brackets is phosphorylated in mice but not conserved in humans [66]. The 
lines below the alignment denote the individual P0 domains. The P0ct neuritogenic segment is 
represented by the red box. 
Figure 1. The molecular structure and conservation of P0. (a) The domain architecture and membrane
topology of P0. The individual protein domains are labeled, with the highly positively charged P0ct
highlighted in red. Fatty acylation of P0ct is shown in green, with the position Cys182 in P0ct indicated
with an asterisk. Phospholipids and glycolipids are shown with white and gray headgroups, respectively.
TM, transmembrane. (b) Structures of the rat (blue; PDB ID 1NEU [37]) and human (red; PDB ID
3OAI [40]) P0 Ig-like domains. The conserved disulfide bridge is indicated with an arrow. (c) Sequence
alignment of the predominant P0 isoform from selected vertebrates. The signal sequence has been
omitted, and the numbering and secondary structure labels correspond to human P0. The disulfide-linked
cysteines (asterisks), the fatty acylation site (F), the glycosylation site (S), and the Gly zipper (G) motif in
the transmembrane domain are indicated. Known phosphorylation sites are labelled (P). The P-site in
brackets is phosphorylated in mice but not conserved in humans [66]. The lines below the alignment
denote the individual P0 domains. The P0ct neuritogenic segment is represented by the red box.
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P0 is a target for post-translational modifications (PTM). The Ig-like domain contains a conserved
N-linked glycosylation site, which commonly displays the human natural killer-1 (HNK-1) epitope [67],
a major glycan present in the nervous system. This is a prominent modification of the Ig-like
domain [68], given its relatively small size of ~120 residues. In P0ct, a conserved cysteine, Cys182,
is a fatty acylation site and most often palmitoylated [69,70]. This modification is essential for the
formation of compact myelin and likely to anchor P0ct to the membrane, enhancing its association
and increasing the half-life of P0 [71]. Additionally, P0ct contains numerous phosphorylation sites,
including the YAML motif (residues 220–223) and several Ser residues in the C-terminal region of
P0ct [66,72–75]. It is noteworthy that P0ct harbors a neuritogenic sequence, which in rodents, when
injected as a peptide, induces experimental autoimmune encephalomyelitis [76]. This peptide adopts
a kinked, partially oriented helical conformation under membrane-like conditions that are based on
simple model lipid compositions [41].
3. P0 is the Executive PNS Membrane Stacker
In PNS myelin, P0 is responsible for the formation of the intraperiod line (IPL)—the 5-nm narrow
intramyelinic compartment, where apposing Ig-like domains adhere to one another, bringing the
two myelin membranes together [42,77,78]. During PNS myelination, the first close intermembrane
contacts are formed by the extracellular leaflets of the Schwann cell membrane [79–81]. The initial
intermembrane distance is somewhat larger than in compact myelin, and upon compaction, the
shortening of this distance to form the double intraperiod line held together by P0 may involve e.g., the
rearrangement of apposing P0 Ig-like domains [68], the removal of myelin-associated glycoprotein [82],
or the degradation of large glycans [83]. Initially, the periodicity of myelin was described in early
electron microscopy (EM) and diffraction experiments [7,84–86]. Later, this periodicity was found to
stem from the presence of P0 [42], and the crystal structure of the P0 Ig-like domain provided atomistic
clues into the molecular architecture [37], which fell under scrutiny of modeling approaches that also
considered the swelling of the IPL in different ionic conditions and pH values [38,87,88]. In early EM
studies, the IPL was resolved as a distinct double structure [89], and recently, a zipper-like framework
of isolated bovine P0 reconstituted in model lipid membranes was described using cryo-EM, whereby
apposing Ig-like domains from either model membrane are in close contact, with lateral P0 molecules
being more separated (Figure 2a) [41]. Similar homophilic interaction was observed in the rat P0
extracellular domain crystal structure [37], and an arrangement with hydrogen bonds between the
backbone atoms of Ala76 of two apposing Ig-like domains has been proposed. In this scheme, the
main adhesive property arises from an interaction between Arg74 and His81 of the first and second
Ig-like domains, respectively (Figure 2b) [38]. In this setting, the C-terminal end of the Ig-like domain,
which is followed by the transmembrane helix, would face the membrane [41]. Both Arg74 and His81
are highly conserved (Figure 1c) [28], and the H81R mutation is linked to severe forms of CMT, directly
reducing the adhesive capabilities of P0 [90–92]. Mutations in Ala76, as well as the adjacent Asp75, are
also linked to CMT [32]. The described intermolecular interactions combined with stabilizing lateral
interactions could lead to the formation of large adhesive protein surfaces and be sufficient for forming
the IPL [41]. The Ig-like domain is glycosylated at Asn122 [67,93], which sits close to the membrane
and could interact with glycolipids or adjacent P0 molecules. This might have relevance in the overall
positioning of the Ig-like domains for productive adhesion, as suggested earlier through molecular
modeling studies [68]. Indeed, the removal of Asn122 and addition of new glycosylation sites in the
Ig-like domain have been linked to adhesion loss and CMT [93–95], as will be discussed below.
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The lateral oligomeric arrangement of P0 remains to be accurately determined, despite several
studies having focused on the oligomerization of P0 [37,39,43,96]. The oligomeric state has been
suggested to arise from the dimerization of transmembrane domains via an internal Gly zipper, which
is conserved among terrestrial vertebrates (Figure 1c). Furthermore, the CMT-linked G164R mutation,
located in the middle of the Gly zipper, abolishes dimerization [65]. However, this Gly residue is not
present in Xenopus laevis, yet its P0 retains the ability to form dimers and tetramers that are resistant to
various denaturants and detergents, and remains stable over a wide pH range [39]. An ultrastructural
architecture involving dimerized Gly zippers has been proposed [65]. This model assumes the presence
of lateral tetramers of Ig-like domains; in recent cryo-EM studies, monomeric Ig-like domains were
observed with constant lateral spacing in myelin-like stacks composed of model lipid membranes [41].
On the other hand, P0ct might also be involved in lateral oligomerization, as its folding is altered
between different detergents, much like the oligomeric state of full-length P0 [41]. Additionally, P0ct
was found to affect the homophilic adhesion of the Ig-like domains in transfected non-myelinic cells
expressing P0 [97].
P0 is particularly important for PNS myelin, as its absence compromises the formation of
compact myelin [98–100]. Mouse models lacking P0 cannot be rescued by PLP—the highly abundant
transmembrane protein thought to be a major contributor to intramyelinic membrane stacking in the
CNS [100]. This is not the case in the opposite setting, and P0 is able to replace PLP to some extent in the
CNS [101]. However, replacement of PLP with P0 in the mouse CNS has two remarkable consequences:
(1) the CNS IPL spacing increases to a similar width as in the PNS, and (2) Schmidt-Lanterman incisures
(SLIs), the PNS-specific transversal veins of cytoplasm within compact myelin, can also form in CNS
myelin [102]. Therefore, while P0 is normally not present in SLIs, its presence is required for SLI
formation. The roles of PLP and P0 have co-evolved [103], and while several P0 isoforms are present in
both CNS and PNS myelin of certain cartilaginous fish [104], it has eventually been lost from the CNS
in terrestrial vertebrates and been replaced by PLP among other proteins [103,104]. Normal SLI-like
cytoplasmic veins in the CNS are present in significantly lower numbers than SLIs in the PNS [101,102],
mostly forming longitudinally [105], but also transversally [106], and their formation is regulated by
MBP and 2′,3′-cyclic nucleotide 3′-phosphodiesterase [107]. In addition to P0, MBP levels also control
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SLI morphology in the PNS [48], revealing an overlapping function. This is of interest due to the
similar physicochemical properties of MBP and P0ct.
The Ig-like domain of P0 has been found to interact with PMP22 [108,109], an abundant tetraspan
protein in PNS myelin, and the interaction might have relevance in membrane stacking, as a specific
ratio of P0 to PMP22 is required to maintain normal myelination [110]. PMP22 resembles PLP
topologically, and it belongs to the claudin family of adhesion proteins [111,112]. PMP22 has been
demonstrated to act as a membrane stacker [113], but PMP22 cannot rescue myelination when P0 is
missing [114]. The periodicity of PNS myelin varies with pH [115], and comprehensive experiments
establishing the role of electrostatics and proteins in periodic variation that stem from pH and ionic
strength have been conducted [87,88], suggesting that the swelling of the IPL in PNS myelin largely
depends on the abundance of negatively charged residues in the P0 Ig-like domain. This, however, was
concluded before the structural characterization of the domain, and now, the width of the IPL is thought
to be mostly governed by the apposition of Ig-like domains, as illustrated in Figure 2a. Recently, the
effect of acidic pH was suggested to be a consequence of P0 Ig-like domain denaturation [116], and the
observed closer packing of the membranes that form the IPL at low pH could reflect PMP22 being
able to maintain a compact IPL. This suggests that IPL stability after myelin formation might not
immediately require P0, but future studies are certainly required to shed light on the matter. PMP22
has been linked to the formation of lipid rafts in Schwann cells [117], and P0 is known to localize to
rafts of certain lipid composition [118]. Moreover, P0 trafficking is dependent on membrane cholesterol
content [119] (see below).
Due to available structural information, the Ig-like domain and its role in defining the spacing of
the IPL have been the focus of several studies. In contrast to the literature published on the Ig-like
domain and IPL formation, studies focusing specifically on the structure-function relationships of
P0ct account for a small fraction of experimental data available for P0 [41,44,58–61]. MBP and P0ct
share similar physicochemical characteristics, which potentially confers P0ct with MBP-like functions.
These might include a role in the formation of cytoplasmic cavities [107]. Importantly, based on in vitro
studies on how P0ct interacts with model lipid bilayers, P0ct might mediate the packing between
membranes that form the cytoplasmic compartment [41,44]. Central results supporting this hypothesis
arose from experiments where P0ct irreversibly associated with simplified model membrane systems
with a similar affinity as MBP [41,44,63] and aggregated lipid vesicles together, producing membrane
spacings typical for the MDL [41,44]. The effect was dependent on the dosage of P0ct, the net charge
of the lipids, ionic strength, and the presence of Ca2+ [41,44,62]. Similar chemistry, however, might
not be sufficient alone: for the ability to stack phospholipid membranes, a structural architecture
that enables stacking must be achieved. In the case of MBP, this architecture has been subject to
decades of research [17]. While evidence obtained through comparison of PNS myelin isolates from
wild-type and MBP-deficient shiverer mice suggested that MBP would only bind to the membrane
headgroups [120,121], a range of subsequent biophysical studies indicate that MBP also partially inserts
into the bilayer core [122–127]. The accurately determined protein-free structure of the myelin lipid
bilayer [128] is altered in this process [63,124]. Based on earlier literature and recent experimental
data, a membrane stacking mechanism for MBP has been proposed [63], although further confirmatory
studies using other experimental approaches are certainly required, especially those that involve
isolated natural myelin.
Experimental evidence suggests that P0ct differs from MBP in one noteworthy aspect during
membrane association: when MBP binds to a single membrane, a partially folded intermediate
state is formed, which can further adhere to a second membrane given that MBP reaches a critical
concentration [12,63]. On the other hand, P0ct as a free polypeptide completely embeds into model
membranes (Figure 3a) [44]; however, more studies regarding the binding mode are needed. This
association is supported by the fact that P0ct is kept very close to the membrane in vivo, not only by the
transmembrane domain, but also through the fatty acylation of Cys182 [61,71]. Since P0ct is roughly
half of the size of MBP, the ability of P0ct to span the MDL is lower compared to MBP, suggesting
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that P0ct may stack membranes through a different molecular arrangement than MBP. This is also
supported by past literature describing a slightly widened MDL in the PNS of shiverer mice, which lack
functional MBP [77].Cells 2020, 9, 1832 7 of 20 
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(b) Possible arrangements of P0ct and two apposing bilayers in a membrane stack. P0ct is drawn in red
with the rest of P0 in blue.
Different membrane stacking modes might exist for P0ct in the MDL (Figure 3b). The stacking
mode may be homophilic, which is possible given the amount of P0 in PNS myelin. P0ct being enriched
in otherwise negatively charged membranes would neutralize the membrane charge, which could
result in weak attractive interactions between adjacent P0ct segments. Another mechanism could
include P0 molecules swapping their tails into th apposing membrane, allowing P0ct to span the
MDL and thus define its width. In the absence of experimental data, unimolecular stacking involving
a single P0 molecule that interacts with an apposing membrane cannot be excluded. Regardless of the
exact mechanism, P0ct can certainly bridge lipid bilayers together at least in vitro [41]. Importantly,
a missense mutation linked to a CMT phenotype with abnormally dense and thick myelin sheaths,
D224Y, showed creased activity in biophysical xperiments, in which mutated P0ct interacted with
vesicles composed of synthetic lipids [44].
When considering the formation of the MDL, MBP is an indispensable component of CNS
myelin [17], being present in moderate amounts in the PNS [14]. P2, the small β-barrel that may
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function as a lipid transporter in myelin maintenance [46], is similarly capable of stacking membranes
at a near-crystalline level of order in vitro [21,129]. Unlike MBP and P0ct, however, P2 binds membrane
surfaces in a reversible manner [21,130], which could enable P2 to have a more transient role in compact
myelin. This has implications e.g., during the maintenance of myelin via lipid replenishment, which is
a pre-requisite for the long-term integrity of myelin [131–135]. P2 is an important component of PNS
myelin, as several mutations lead to CMT [136–140] by affecting the structure-function relationships
of P2 [141]. MBP and P2 stack membranes synergistically in vitro [46]. Despite these observations,
mice deficient in both MBP and P2 develop normal-appearing PNS myelin [46,48], whereas the
lack of P0 results in a severe dysmyelinating phenotype with large non-compacted ultrastructural
regions [98–100]. This does not imply that MBP is redundant in PNS myelination; mice lacking both
P0 and MBP completely lack the MDL, while the presence of MBP in P0-deficient animals produces a
slightly less dramatic phenotype [142]. Furthermore, mutations in P0ct that directly interfere with
its structure-function relationships or PTMs influence its function in myelin, and thus the myelin
phenotype [44,72,143,144]. It is therefore plausible that P0ct functions as the executive membrane
stacking molecule in the cytoplasmic apposition, through its ability to compensate for the functions
of MBP and P2 in PNS myelin—at least in the developing nervous system [46]. As soluble proteins,
MBP and P2 are completely translated in the cytoplasm. When MBP performs its membrane stacking
function, local translation of free MBP allows spontaneous interaction with membranes, and the
formation of compact myelin [63]. On the other hand, when MBP remains soluble, it may have other
functions [12,17]. The solubility of MBP distinguishes it from the expression pattern and trafficking of
P0; P0ct is likely to always remain membrane-embedded and have less spatial freedom.
4. The Expression and Trafficking of P0
During PNS development, SCPs proliferate and migrate along axons from the neural crest,
differentiating into Schwann cells. This process is regulated by a multitude of molecular factors [145],
most importantly neuregulin 1 (NRG1). While Schwann cells develop in the presence of other glia and
neurons, they are destined to become either myelinating or non-myelinating Schwann cells, mostly
through dose-dependent axo-glial NRG1 signaling [146]. The presence of NRG1 type III is of particular
importance [147,148], as low NRG1 type III will direct Schwann cells to form amyelin, or Remak
bundles, which lack compacted membranes. Conversely, high NRG1 type III levels promote the
formation of myelinating Schwann cells, and the degree of myelination directly correlates with the
amount of active NRG1 type III [146].
The expression and targeting of P0 are illustrated in Figure 4. The translation of P0 begins in the
cytosol, and the N-terminal signal sequence targets it to the ER. The signal sequence is cleaved, and
most of the P0 chain is translated as it is transported through the membrane. The Ig-like domain folds
in the ER lumen, potentially through assisted disulfide bond formation and chaperone activity [55,149].
The transmembrane domain anchors P0 to the membrane, and the final translated segment is P0ct.
The fatty acylation of P0ct at Cys182, which increases the lifetime of P0 [71], is likely to occur soon after
P0 is fully translated. At this point, P0ct most likely has already entered the membrane, as suggested
by recent data [41], especially since the ER membrane is negatively charged due to the presence of
phosphatidylinositol [150]. In the ER, P0 is glycosylated at Asn122 [67], followed by its trafficking
to the Golgi membranes. Here, the N-glycan of P0 is modified to become mature HNK-1 [67], and
P0 is targeted to the plasma membrane [151–153]. This trafficking is dependent on at least the
phosphorylation of P0ct at Ser228 and Ser233 [73] as well as the presence of a YAML motif [154].
This motif contains Tyr220, which becomes phosphorylated at the peak of myelination [75]. Increased
phosphorylation of P0ct, in general, is connected to active myelination [155].
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basal level and target it to the plasma membrane. This process normally does not form myelin-like
structures, but in myelinating Schwann cells that proliferate from SCPs at high NRG1 levels, P0
targeting shifts to the mesaxon via unknown mechanisms. Potential myelination-involved factors
include intermolecular interactions between P0 molecules, the phosphorylation of P0ct, and/or altered
membrane lipid compositions. The changing lipid environment between different membranes affects
the partitioning and trafficking of P0 [118,119,150].
A basal level of P0 can be detected already in neural crest cells and SCPs [156], and in mature
Schwann cells, P0 is very abun ant [47]. During myelination, P0 is trafficked to the leading mesaxon
here it ventually performs its structural f nction and drives myel n compaction [152]. However, it is
important to realize that the pre ence of P0 in Schwan cells does not imply that myelin has formed
in the first place, or will ever form [47]. Ig-like domains will not assemble i t zippers and P0ct will
not stack membranes only because P0 is present. In fact, P0 functions not involved in myelination
have been proposed, including axo-glial crosstalk, as the lack of P0 results in axonal degeneration [98].
Moreover, such functions appear to have specifically evolved for PNS myelin, as replacing PLP with P0
in the CNS produces similar axonal degeneration, which essentially arises from an abnormal phenotype
at the myelin paranodes [101,102].
As with MBP in the CNS, the effect of P0 on myelination is dose-dependent [110,157,158], and
overexpression of P0 has dire consequences for the sorting of naked axons and the correct formation of
myelin (Figure 5) [110,157]. In the mature myelin sheath, P0 is very abundant, and most of it is present
in compact myelin. The expression of MBP in the CNS is targeted by transporting the MBP mRNA
to where translation is required [159–163]. In the case of P0, other temporal mechanisms that target
mature P0 to the esaxon are required: Golgi-derived vesicles that carry P0 are transported to the
spirally rapped mesaxonal membrane via microtubules [151,153]. Thus, elevated expressio of P0
n eds to b initiated, but at the same time, its trafficking nee s to be controlled to avoid crowding in
the ER, Golgi, and plasm membranes. Currently, what exactly triggers this expression an trafficking,
let alone which fac ors are involved in the vesicular transport of P0 pecifically o th mesaxon, remains
unknown. Control of P0 expression is a crucial requirement, as P0 overexpression would result in the
halting of myelin wrapping and compaction, and eventually dysmyelination [110,157]. The YAML
Cells 2020, 9, 1832 10 of 21
motif and phosphorylation state of P0ct might be involved, as might the interaction and co-localization
of P0 with PMP22, but further studies are required in these aspects. Additionally, how SLI formation
and PNS myelination tie together from the perspective of P0 expression and trafficking is another
enticing area of scientific interest.
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phosphorylation has been linked to myelination, phospho-P0ct might become exposed and function as a
mesaxonal targeting signal, and be incapable of membrane stacking before it reaches the nascent myelin
multilayer. Middle: P0 mutations result in demyelination through different mechanisms, including
loss of trafficking, UPR activation via overwhelming ERAD, and loss of adhesion by disturbing the
structure and function of P0. Right: in model systems, overexpression of P0 results in P0 targeting to the
abaxonal, periaxonal, and mesaxonal membranes, which results in complications that halt myelination.
It also affects the sorting of axonal bundles, implying that P0 is involved in axo-glial signaling.
There are essenti ly two categories of P0 mutations that can induce a demyelinating phenotype:
(1) nonsense and frameshift mutations deleting large segments of P0, resulting in loss of structure
and function, and (2) missense mutations that disturb the structure and function of P0 required in
stable membrane st cks, cause in racellular folding issues with P0, or mislocalize P0. While the effect
of nonsense and frameshift mutations is ra er tr vial, missense mutations can have various effects
on P0 [32], which may be immediate or depen on gene dosage [144]. Missense mutations include
amino acid changes that result in l st or alter d P0 function, such as the H81R mutation discussed
above. Anot er CMT mutation, D224Y, enha ces the m mbr n stacking ability of P0ct i model
embrane system , and it is linked to an unusually de se a d thick compact myelin phe otype in
affected patients [44,143,144]. Loss of the conserv d glycosylation site by the N122S mutation results
in a relatively mild demyelinating phenotype [94,164], most likely due t weakened adhesio at the
IPL. The S63C mutation has been reported to directly affect the stacking function of P0, resulting in an
increased IPL width that stems from dimerizing Ig-like domains via Cys63-mediated intermolecular
disulfides [33,165]. Significantly, the effect of this mutation could be reversed through the use of
reducing agents, essentially reverting to the phenotype of native-like myelin in mutant animals [165].
On the other hand, missense mutations might also directly influence the trafficking of P0. This could
be the case for A221T within the YAML motif, as the mutant P0ct in vitro behaves as the wild-type
protein [44], but in vivo, the mutation causes DSS together with a second mutation in the Ig-like
domain [166]. In mutations that affect P0 trafficking, the underlying mechanism could arise from
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either loss of targeting or mistargeting, as in P0 overexpression models [110,157]. Another noteworthy
mutation is D61N, which introduces a new glycosylation site in the Ig-like domain, causing myelin
outfoldings and partially retained P0 in the Golgi membranes [95]. This suggests that P0 trafficking is
influenced either by Asp61 or nearby amino acids, or an increase in glycosylation. The P0 retainment
in the Golgi might arise from a slowdown of P0 processing due to the increased level of glycosylation.
In turn, the outfoldings might be a direct result of P0 mistrafficking to the abaxonal membrane instead
of the mesaxon, resulting in stacking artifacts on the Schwann cell surface.
Several neuropathy mutations in the Ig-like domain and P0ct have been directly linked to
UPR [33,34,167,168], which is a condition of the ER that severely stresses the cell and eventually
promotes pro-apoptotic mechanisms (Figure 5) [169]. UPR arises from prolonged accumulation of
misfolded and unfolded proteins that cannot be cleared rapidly enough through ERAD [170]. ERAD
was recently demonstrated to harbor a neuroprotective role in Schwann cell pathology, specifically
P0-borne CMT type 1B, as the P0 S63del mutant, which is incapable of folding and accumulates in the
ER, is cleared through ERAD [36]. The exact pathological effects of other P0 mutations that induce
UPR are subjects for future studies, although the overloading of ERAD may be involved in most cases.
Possible molecular mechanisms include misfolding, unfolding, and unspecific aggregation of P0. This
includes mutations that affect disulfide bond formation in the Ig-like domain, although a mutation of
the conserved disulfide-bonded Cys50 did not impair the membrane trafficking of P0, but caused a lack
of adhesion [55]. Another mechanism involves significantly altered P0 expression and/or trafficking
patterns that essentially causes nascent P0 to be retained in the ER, overloading its folding machinery.
Again, the YAML motif is potentially involved, as the efficient clearance of P0 from the ER would likely
be affected if P0 trafficking is blocked or hindered, especially during accelerated P0 expression.
5. Future Directions
A key open aspect from an ultrastructural perspective is the oligomerization mechanism of P0.
Whether and how P0 forms tetramers, as suggested by earlier reports [37,39,43,65], is a major open
question to answer, as Ig-like domain-mediated tetramerization might not be relevant per se in the
light of recent observations [41]. The transmembrane domain Gly zipper is likely to play a role in
oligomerization [65], but the sensitivity of P0 oligomerization to different detergents [39,43] suggests
that P0ct could be involved, as its folding in vitro does depend on the choice of detergent [41]. Given
the substantial amount of P0 compared to other PNS myelin proteins [14], and the stacking architecture
P0 adopts in myelin-like membranes [41], lateral oligomers must exist, but how do they actually
form? To assess this, the ambitious goal of acquiring an atomic resolution structure of full-length P0
in a membrane of native myelin composition would help answer the question. Thus far, no reports
describing the purification of recombinant full-length P0 exist, while highly pure recombinant P0 will
be needed for such studies, instead of protein extracts from native sources. As crystallization might be
problematic, a cryo-EM approach will be useful in P0 characterization [41]. The preparation of 2D
and 3D ordered samples from highly purified materials should enable the use of hybrid structural
biology techniques, including cryo-EM, tomography, atomic force microscopy, or grazing-incidence
scattering methods, for unraveling the high-resolution details of P0 assembly in myelin. In an optimal
setting, these methods could be employed using lipids derived from natural myelin, which differs
substantially in lipid composition from simpler model membrane systems that were employed in the
characterization of P0ct and full-length bovine P0 [41].
How is P0 trafficked to the mesaxon during myelination? The involvement of the Golgi complex
and Golgi-derived vesicles has been established [151,153,157], but the trigger mechanism remains
elusive. While the Ig-like domain resides in the lumen of the endomembrane system before reaching
the plasma membrane, reports that favor the involvement of the extracellular domain in trafficking are
scarce [95]. On the contrary, P0ct is more likely to be involved: not only does it contain the YAML
motif involved in trafficking [154]; its multiple phosphorylation states during myelination definitely
have a role in bringing P0 to its target compartment [73,75]. In addition, the role of other proteins in
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the trafficking and function of P0 is still unclear. PMP22 is a known interaction partner and needs to be
present in healthy PNS myelin [108–110], but other proteins might be involved in the correct targeting
of P0, and even harbor synergistic effects when P0 establishes membrane stacks.
P0ct is special in two interconnected aspects. Firstly, it is small and has unique chemical attributes,
most notably its high abundance of Arg and Lys that grant it a high positive net charge. Charge-altering
modifications, such as phosphorylation, will influence the net charge of P0ct, which in humans contains
only 69 residues. Since trafficking signals are commonly found in cytoplasmic domains of membrane
proteins, this might regulate P0 trafficking. The known phosphorylation sites in P0ct are clustered within
a very narrow sequence stretch [66,72–75]. Modifying these sites at the correct time during myelination
would change the electrostatic properties of P0ct, allowing spatiotemporal regulation of membrane
association and potential stacking. Secondly, the lipidic microenvironment seems to determine P0ct
behavior in vitro. P0ct associates with model membranes through electrostatic attractions, which
arise from both the amino acid sequence of P0ct and the membrane lipid composition. While the ER,
Golgi, and plasma membrane cytoplasmic leaflets are rich in negatively charged lipids, the ratio of net
neutral and negatively charged lipids varies between each compartment. Additionally, cholesterol
and sphingomyelin contents gradually change, while traversing from one subcellular volume to
another [150], which directly impacts the formation of membrane lipid rafts [171–173]—another aspect
influencing P0 localization [118]. Cholesterol is of low abundance in the ER [150], but is a factor
of pivotal importance during myelination [174]. Recently, several myelin-specific transmembrane
proteins, including PMP22, have been shown to partition into cholesterol-rich membrane domains, and
the partitioning appears to be dependent on protein stability [175,176]. Logically, the most important
proteins would assemble together with cholesterol, as P0 does [119].
Considering the points made above, it is enticing to speculate how PTMs in P0ct and the gradually
changing membrane composition along the P0 trafficking pathway could enable microscopic changes
in the affinity and folding of P0ct, as well as its stacking tendency. As biophysical studies focused on
the structure-function relationships of P0ct in model lipid environments have recently provided useful
information, motivation emerges to study P0ct and P0 in myelin-like lipid compositions, even of natural
origin. Therefore, P0ct is a key target for future studies when considering the spatiotemporal targeting
of P0 to the mesaxon during myelination. After P0 has reached the mesaxon, a lipid-rich environment,
possible phosphatase-enabled activation of densely packed P0 could result in IPL formation and
efficient P0ct-mediated MDL stacking, much like how MBP orchestrates MDL assembly in the CNS [63].
6. Conclusions
Demyelinating conditions have several etiological pathways with different biomolecular origins.
P0 is a fundamental part of PNS myelin and its biogenesis, but also an unfortunate target for CMT and
DSS mutations. Many aspects of P0-linked myelination have unveiled in recent years, yet many open
questions remain. The lateral P0 assembly, the involvement of P0ct, and the P0ct structure during P0
trafficking and oligomerization are subjects for in vitro and in vivo characterization. Unraveling how
P0, together with other compact myelin molecules, achieves its adhesive function at the correct time in
the right place is an absolute requirement for understanding the formation and demise of myelin.
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Abbreviations
CMT Charcot-Marie-Tooth disease




ERAD ER-associated protein degradation
HNK-1 human natural killer-1
Ig immunoglobulin
IPL intraperiod line
MBP myelin basic protein
MDL major dense line
NRG1 neuregulin 1
P0 myelin protein zero
P0ct the cytoplasmic extension of P0
P2 peripheral myelin protein 2
PLP proteolipid protein
PMP22 peripheral myelin protein 22
PNS peripheral nervous system
PTM post-translational modification
SCP Schwann cell progenitor
SLI Schmidt-Lanterman incisure
UPR unfolded protein response
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